As a financial writer, sometimes you get lucky. That proved to be the case when I wrote about Celldex Therapeutics (CLDX)
in January of this year - right before the shares spiked on new-found
optimism for the company's innovative oncology program. Since then, the
company has reported encouraging (albeit confusing) clinical data and
bounced around between $4 and $5.50. Although investors should not
underestimate the risks to this story, these shares still look like an
under-appreciated play on some very difficult-to-treat cancer types.
Please continue here:
Catching Up With Celldex Therapeutics
No comments:
Post a Comment